Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Why big players are pouring millions in THIS biotech stock
08:43am, Monday, 01'st Sep 2025
Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space. The company uses CRISPR gene editing technology to develop treatments, and whil
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
12:24pm, Friday, 15'th Aug 2025
Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concer
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
12:21pm, Friday, 08'th Aug 2025
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
08:17pm, Thursday, 07'th Aug 2025
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Brittany Chaves - Corporate Participant David Lebwohl - Executive VP & Chief
Intellia (NTLA) Q2 Revenue Jumps 106%
11:23am, Thursday, 07'th Aug 2025
Intellia (NTLA) Q2 Revenue Jumps 106%
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
09:41am, Thursday, 07'th Aug 2025
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $1.31 per share a year ago.
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 01'st Aug 2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Intellia (NTLA) To Contact Him Directly To Discuss Their Options
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
07:30am, Thursday, 31'st Jul 2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
10:45am, Wednesday, 30'th Jul 2025
An updated edition of the June 27, 2025, article.
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
08:00am, Friday, 18'th Jul 2025
Investors often react fast to news. We see it with earnings announcements. And in biotech/pharma, we see it in response to news about drug trials. We saw that in spades on 5/29/25 for gene editor Inte
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
04:27pm, Tuesday, 15'th Jul 2025
In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a previous ceiling of 6,500, and flagged three stocks investors should have on
Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future
10:54am, Thursday, 10'th Jul 2025
Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth.
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 07'th Jul 2025
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
10:50am, Monday, 07'th Jul 2025
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
